Clearmind Medicine (FRA:CWY0) Beta: -1.7398 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CWY0 Clearmind Medicine Inc FRA:CWY0
22 GF Score
Price €22.56
! 1 Warning Sign
View Full Analysis

What is Clearmind Medicine Beta?

Clearmind Medicine FRA:CWY0 22 Beta is -1.7398 as of Jul. 17, 2026. GuruFocus rates FRA:CWY0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-17), Clearmind Medicine's Beta is -1.7398.


Clearmind Medicine  (FRA:CWY0) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Clearmind Medicine Beta Related Terms


Clearmind Medicine Beta Historical Data

* Premium members only.

The historical data trend for Clearmind Medicine's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearmind Medicine Beta Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 -1.58 -2.39

Clearmind Medicine Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.20 -0.93 -2.39 -2.49 -2.80

FRA:CWY0 vs ONCO, PPCB, REVB: Beta Comparison

For the Biotechnology subindustry, Clearmind Medicine's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearmind Medicine Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Beta distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Beta falls into.


FRA:CWY0
22GF Score
Clearmind Medicine Inc FRA:CWY0
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearmind Medicine Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -1.7398 mean?
Clearmind Medicine (FRA:CWY0) has a Beta of -1.7398 as of Jul. 17, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Clearmind Medicine and its competitors.
Is Clearmind Medicine's Beta too high?
Clearmind Medicine's current Beta is -1.7398. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's Beta compare to ONCO and PPCB?
Clearmind Medicine's Beta of -1.7398 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Clearmind Medicine and its competitors. Clearmind Medicine's current Beta is -1.7398. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (FRA:CWY0) has a current Beta of -1.7398. The current Beta is -1.7398. Clearmind Medicine's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Clearmind Medicine (FRA:CWY0), the current Beta is -1.7398 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clearmind Medicine Business Description

Other Exchanges CMND:USA
Address 101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H1A5
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score

Get the complete analysis for FRA:CWY0

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.56
Price